FDA 483 - Viva Pharmaceutical Inc - October 25, 2024

An FDA inspection of Viva Pharmaceutical Inc. in Richmond, British Columbia, revealed significant deficiencies across multiple areas of drug manufacturing. Observations included inadequate equipment cleaning, critical failures in the quality control unit's data integrity and oversight, and insufficient investigations into out-of-specification results. Additionally, the facility showed poor maintenance with damaged production room flooring.